Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
Checkpoint inhibitor (CPI) based immunotherapy (i.e., anit-CTLA-4/PD-1/PD-L1 antibodies) can effectively prolong overall survival of patients across several cancer types at the advanced stage. However, only part of patients experience objective responses from such treatments, illustrating large individual differences in terms of both efficacy and adverse drug reactions. Through the observation on a series of CPI based clinical trials in independent patient cohorts, associations of multiple clinical and molecular characteristics with CPI response rate have been determined, including microenvironment, genomic alterations of the cancer cells, and even gut microbiota. A broad interest has been drawn to the question whether and how these prognostic factors can be used as biomarkers for optimal usage of CPIs in precision immunotherapy. Therefore, we reviewed the candidate prognostic factors identified by multiple trials and the experimental investigations, especially those reported in the recent 2 years, and described the possibilities and problems of them in routine clinical usage of cancer treatment as biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“And inhibition of TGFβ signaling provokes antitumor activities and promotes tumor susceptibility to anti-PD therapies in colorectal cancer as well as urothelial cancer (Mariathasan et al., 2018; Tauriello et al., 2018).”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 3×
“provides with an opposite finding that plenty of Bacteroidales are related to poor response to anti-PD-1 (Gopalakrishnan et al., 2017).”
BackgroundResultInfluentialCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“And oral administration of Bifidobacterium alone generates equal effect on tumor eliminating as anti-PD-L1 does, indicating its potentially important role in strengthening immune functions (Sivan et al., 2015).”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 3×
“…September 2018 | Volume 9 | Article 1050 of gut microbiota, some studies indicate a positive correlation between responses and Bacteroides species (Vetizou et al., 2015; Frankel et al., 2017), whereas the study of Gopalakrishnan et al. provides with an opposite finding that plenty of…”
BackgroundResultGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 1×
“Similarly, another study on patients with melanoma also reveals a correlation between response to anti-PD1 and abundance in more diversified bacteria, including Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium (Matson et al., 2018).”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“Tumor-intrinsic activation of WNT/β-catenin signaling pathway results in subdued CCL4 expression and subsequent precluded dendritic cell (DC) recruitment and DC-mediated T-cell activities, thus leading to resistance to anti-PD-L1 and anti-CTLA-4 therapies (Spranger et al., 2015).”
BackgroundMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 2×
“Although great success has been achieved with CPI based immunotherapy, large individual differences were noticed in terms of treatment outcomes (Gibney et al., 2016; Manson et al., 2016; Pitt et al., 2016; Topalian et al., 2016; Zou et al., 2016; Nishino et al., 2017), which varied among different cancer types.”
BackgroundRadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434 · cited 2×
“Conventional therapies targeting tumor cells, including radiotherapy and chemotherapy, also exert enhanced antitumor activities together with anti-PD therapy through multiple interacting mechanisms (Deng et al., 2014a; Shalapour et al., 2015; Sharabi et al., 2015; Twyman-Saint Victor et al., 2015; Shaverdian et al., 2…”
BackgroundImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Self-citationDeng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“The process of neoantigen recognition is attenuated by expression of PD-L1 and some other immunosuppressive ligands (Pages et al., 2005; Llosa et al., 2015).”
BackgroundNeoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099 · cited 2×
“Evidence from clinical trials suggests the positive correlation between high tumor mutational loads and improved clinical efficacy of ICB-based therapies (including anti-PD-1, anti-PD-L1, and anti-CTLA-4) in NSCLC and melanoma (Snyder et al., 2014; Rizvi et al., 2015; Van Allen et al., 2015; Hugo et al., 2016; Forde e…”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 1×
“Accordingly, epigenetic reprogramming drugs to facilitate T cell trafficking (Tan et al., 2007; McCabe et al., 2012), and targeting TNF family signaling pathways to strengthen T cell functions (Tolcher et al.”
BackgroundT cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685 · cited 1×
“Among complicated pathways of immune system, interactions of cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4) with CD80/CD86, and programmed cell death 1 (PD-1) with programmed cell death ligand 1 (PD-L1) has been considered to act as “brakes” on the immune system (Linsley et al., 1991; Freeman et al., 2000; Schil…”
BackgroundSpranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · cited 12×
“Prostaglandin E2 (PGE2) and its key synthesizing enzyme cyclooxygenase 2 (COX2) can induce and recruit MDSCs in TME, and inhibition of COX2 has synergized anti-PD therapy in pre-clinical models (Li et al., 2016).”
BackgroundInfluentialT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 2×
“Particularly, in patients with KRAS-mutant lung adenocarcinoma, STK11/LKB1 alterations are significantly associated with PD-L1 negativity and promote resistance to PD1 inhibitors (Skoulidis et al., 2018).”
BackgroundPredictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635 · cited 3×
“Although great success has been achieved with CPI based immunotherapy, large individual differences were noticed in terms of treatment outcomes (Gibney et al., 2016; Manson et al., 2016; Pitt et al., 2016; Topalian et al., 2016; Zou et al., 2016; Nishino et al., 2017), which varied among different cancer types.”
BackgroundKoyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465 · cited 2×
“As a pleiotropic and critical cytokine in host immune activities and tumor rejection (Dighe et al., 1994; Kaplan et al., 1998), IFNγ exerts its effects through a complex and orderly signaling pathway (Ikeda et al., 2002).”
BackgroundBystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370 · cited 1×
“Moreover, these CD8 + TILs lack the expression of CD39, suggesting that measuring CD39 expression could be an effective approach to select the patients with high possibility of virus infection (Simoni et al., 2018).”
BackgroundDistinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 1×
“In turn, anti-PD blockades also increase the number and restore the function of effector T cells during the treatment (Wei et al., 2017; Zhou et al., 2017).”
BackgroundAllele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
Self-citationCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · cited 1×
“high level of clinical response, providing a novel perspective that virus-positive status may contribute to success of antiPD-1 therapy (Nghiem et al., 2016).”
BackgroundGenomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249 · cited 8×
“Interestingly, studies adopting the same approach newly discover that the loss-of-function mutations in PBRM1, which encodes a subunit of a SWI/SNF chromatin remodeling complex (the PBAF subtype), might improve the responsiveness to ICBs due to activation of JAK-STAT signaling pathway and elevated sensitivity to IFNγ…”
BackgroundInfluentialEpigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · cited 1×
“And it has been proved that epigenetic modulators can restore T cell activities and increase T cell infiltration, thus strengthening the therapeutic efficacy of PD-L1 blockade (Peng et al., 2015).”
BackgroundFuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192 · cited 1×
“Distinct from IFNγ, type I IFN within innate immune system is critical for T cell priming and tumor elimination through signaling on DCs and lack of type I IFN will result in limited useful T cells for reactivating of antitumor activities (Diamond et al., 2011; Fuertes et al., 2011).”
BackgroundPatient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., & Lee, P. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30380-7 · Cited by 1,091 · cited 1×
“Conventional therapies targeting tumor cells, including radiotherapy and chemotherapy, also exert enhanced antitumor activities together with anti-PD therapy through multiple interacting mechanisms (Deng et al., 2014a; Shalapour et al., 2015; Sharabi et al., 2015; Twyman-Saint Victor et al., 2015; Shaverdian et al., 2…”
BackgroundType I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034 · cited 1×
“Moreover, an approach to systematically assessing intra- and peri-tumoral T cell infiltration, namely immunoscore, has been considered as a stronger predictor of prognosis as well as response to ICB therapies due to its integrated evaluation of immune features (Mlecnik et al., 2016; Voong et al., 2017).”
BackgroundMonitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023 · cited 7×
“Interestingly, TMB and PD-L1 overexpression is correlated to presence of TILs (Herbst et al., 2014; Nishino et al., 2017).”
BackgroundInfluentialRescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · cited 1×
“It is newly discovered that PD-1/PD-L1 interaction suppresses T cell function primarily by CD28 inactivation, and the rescue of exhausted CD8 + T cells by PD blockades is strongly dependent on CD28 expression, which elucidates the important role of CD28/B7 costimulatory pathway as a response indicator for anti-PD ther…”
BackgroundCyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., Gelber, R. D., & Goldhirsch, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30261-4 · Cited by 973
Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962
Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895 · cited 1×
“Accordingly, epigenetic reprogramming drugs to facilitate T cell trafficking (Tan et al., 2007; McCabe et al., 2012), and targeting TNF family signaling pathways to strengthen T cell functions (Tolcher et al.”
BackgroundIdentification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852 · cited 7×
“Interestingly, studies adopting the same approach newly discover that the loss-of-function mutations in PBRM1, which encodes a subunit of a SWI/SNF chromatin remodeling complex (the PBAF subtype), might improve the responsiveness to ICBs due to activation of JAK-STAT signaling pathway and elevated sensitivity to IFNγ…”
BackgroundInfluentialvan Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
Melanoma genome sequencing reveals frequent PREX2 mutations
Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., Ivanova, E., Watson, I. R., Nickerson, E., Ghosh, P., et al. (2012) · Nature · doi:10.1038/nature11071 · Cited by 756 · cited 1×
“, 2018), which have the highest mutation burdens as well as response rates (Lee et al., 2010; Berger et al., 2012; Topalian et al., 2012).”
BackgroundHigh-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735 · cited 1×
“The baseline frequency of CD14 + CD16-HLADRhi monocytes has also been found to strongly predict the response to anti-PD-1 of patients with melanoma (Krieg et al., 2018).”
BackgroundMaj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733 · cited 2×
“Nevertheless, it is reported that apoptotic Tregs sustain and even amplify their immunosuppressive function via the adenosine and A2A pathways under oxidative stress, which highlights oxidative pathway as a metabolic checkpoint controlling Tregs and thus affecting the effect of anti-PD (Maj et al., 2017).”
BackgroundFrankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.004 · Cited by 709
McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30078-0 · Cited by 664
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E., Dhar, D., Willimsky, G., Ammirante, M., Strasner, A., Hansel, D. E., et al. (2015) · Nature · doi:10.1038/nature14395 · Cited by 611 · cited 2×
“Conventional therapies targeting tumor cells, including radiotherapy and chemotherapy, also exert enhanced antitumor activities together with anti-PD therapy through multiple interacting mechanisms (Deng et al., 2014a; Shalapour et al., 2015; Sharabi et al., 2015; Twyman-Saint Victor et al., 2015; Shaverdian et al., 2…”
BackgroundBaseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549 · cited 2×
“IFNγ, produced primarily by Th1 cells, NKT cells and NK cells (Farrar and Schreiber, 1993; Boehm et al., 1997), is abundantly generated and activated when ICBs enhance T cell responses (Liakou et al., 2008; Peng et al., 2012).”
BackgroundGenetic Mechanisms of Immune Evasion in Colorectal Cancer
Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1327 · Cited by 535
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87324 · Cited by 525
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X., & Delgoffe, G. M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0103 · Cited by 520 · cited 1×
“Based on the significant role of metabolic fitness in immune activities, it has been reported that metformin, a broadly prescribed type II diabetes treatment, reverses the resistance to PD-1 blockade which results from hypoxic environments produced by tumors (Scharping et al., 2017).”
BackgroundAdjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
Lee, J. H., Lee, J.-H., Lim, Y.-S., Yeon, J. E., Song, T.-J., Yu, S. J., Gwak, G.-Y., Kim, K. M., Kim, Y. J., Lee, J. W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.055 · Cited by 503
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Gettinger, S., Rizvi, N. A., Chow, L. Q., Borghaei, H., Brahmer, J., Ready, N., Gerber, D. E., Shepherd, F. A., Antonia, S., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9929 · Cited by 501 · cited 14×
“Pembrolizumab was the first inhibitor for PD-1, which was approved as the second-line treatment for unresectable or metastatic melanoma, followed by Nivolumab (for unresectable metastatic melanoma, advanced metastatic NSCLC and advanced metastatic renal cell carcinoma), Atezolizumab (for urothelial carcinoma following…”
BackgroundInfluentialLi, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496
Loo, T. M., Kamachi, F., Watanabe, Y., Yoshimoto, S., Kanda, H., Arai, Y., Nakajima-Takagi, Y., Iwama, A., Koga, T., Sugimoto, Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0932 · Cited by 478 · cited 1×
“Disorders in gut microbiota have been considered to participate in the development of not only colorectal cancer but also extraintestinal cancers (Brennan and Garrett, 2016; Loo et al., 2017).”
BackgroundPD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1187 · Cited by 432 · cited 1×
“IFNγ, produced primarily by Th1 cells, NKT cells and NK cells (Farrar and Schreiber, 1993; Boehm et al., 1997), is abundantly generated and activated when ICBs enhance T cell responses (Liakou et al., 2008; Peng et al., 2012).”
BackgroundOrillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373 · cited 1×
“Reducing the number of MDSCs has been proved to be capable of enhancing antitumor effect of anti-PD1 blockade (Orillion et al., 2017).”
BackgroundXiao, Y., & Freeman, G. J. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1397 · Cited by 368
NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer
Grinberg-Bleyer, Y., Oh, H., Desrichard, A., Bhatt, D. M., Caron, R., Chan, T. A., Schmid, R. M., Klein, U., Hayden, M. S., & Ghosh, S. (2017) · Cell · doi:10.1016/j.cell.2017.08.004 · Cited by 297 · cited 1×
“Moreover, it has been newly discovered that a canonical nuclear factor κB (NF-κB) subunit c-Rel plays an essential role in Treg function, and chemical inhibition of c-Rel impairs Treg-mediated immunosuppression and potentiates the effect of anti-PD-1 therapy (Grinberg-Bleyer et al., 2017).”
BackgroundNishijima, T. F., Muss, H. B., Shachar, S. S., & Moschos, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.006 · Cited by 293 · cited 1×
“Consistent with the decreased activity of immune system in elders, current evidence exhibited that ICB therapy can significantly benefit all age of patients with NSCLC with the exception of patients ≥75 years (Landre et al., 2016; Nishijima et al., 2016; Ferrara et al., 2017).”
BackgroundQuail, D. F., Olson, O. C., Bhardwaj, P., Walsh, L. A., Akkari, L., Quick, M. L., Chen, I.-C., Wendel, N., Ben-Chetrit, N., Walker, J., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3578 · Cited by 277
A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1082 · Cited by 237 · cited 1×
“The comparison of anti-PD-1 sensitive and resistant patients reveals that Tregs partly preclude the efficacy of anti-PD-1 (Ngiow et al., 2015), and that depletion of Tregs can potentiate checkpoint inhibitors (Taylor et al., 2017).”
BackgroundPostow, M. A., Manuel, M., Wong, P., Yuan, J., Dong, Z., Liu, C., Perez, S., Tanneau, I., Noel, M., Courtier, A., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0070-4 · Cited by 232
Ferrara, R., Mezquita, L., Auclin, E., Chaput, N., & Besse, B. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.003 · Cited by 163 · cited 1×
“Consistent with the decreased activity of immune system in elders, current evidence exhibited that ICB therapy can significantly benefit all age of patients with NSCLC with the exception of patients ≥75 years (Landre et al., 2016; Nishijima et al., 2016; Ferrara et al., 2017).”
BackgroundMHC Class I Antigens and Immune Surveillance in Transformed Cells
Aptsiauri, N., Cabrera, T., Garcia‐Lora, A., Lopez‐Nevot, M. A., Ruiz‐Cabello, F., & Garrido, F. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(07)56005-5 · Cited by 145 · cited 1×
“MHC Class I and T-Cell Receptor (TCR) MHC class I presenting antigen to cytotoxic T cells is an essential prerequisite for immune recognition and elimination of transformed cells (Aptsiauri et al., 2007).”
BackgroundLee, K., Shin, K., Kim, G., Song, Y. C., Bae, E., Kim, I., Koh, C., & Kang, C. (2016) · Aging Cell · doi:10.1111/acel.12435 · Cited by 125
Cited by
Digital pathology and artificial intelligence in translational medicine and clinical practice
Baxi, V., Edwards, R., Montalto, M., & Saha, S. (2022) · Modern Pathology · doi:10.1038/s41379-021-00919-2 · Cited by 592
DNA Vaccines—How Far From Clinical Use?
Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457
Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.026 · Cited by 407
Non-Melanoma Skin Cancer: news from microbiota research
Squarzanti, D. F., Zavattaro, E., Pizzimenti, S., Amoruso, A., Savoia, P., & Azzimonti, B. (2020) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1794792 · Cited by 40
Malczewski, A. B., Ketheesan, N., Coward, J. I. G., & Navarro, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624434 · Cited by 22
Metadata
- Authors
- Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-09-20
- Volume
- 9
- Pages
- 1050-1050
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2891457349
- Cited by
- 57
- References
- 89
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.